Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04652739
Other study ID # Lycopene and lichen planus
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date October 1, 2018
Est. completion date March 10, 2019

Study information

Verified date November 2020
Source University of Alexandria
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study was to evaluate the effect of oral lycopene and systemic steroids in the treatment of erosive oral lichen planus and compare between the two therapeutic modalities.


Description:

Twenty erosive lichen planus patients were recruited and randomly assigned in one of two groups, the test (lycopene) and control (corticosteroids) group.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 10, 2019
Est. primary completion date March 3, 2019
Accepts healthy volunteers No
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: - Erosive oral lichen planus patients with severe and extensive painful erythematous, erosive and/ or ulcerative lesions who are in need for systemic corticosteroid therapy Exclusion Criteria: - Pregnant females and smokers. - Patients suggestive of having lichenoid contact/drug reactions. - Patients suffering from any systemic disease as diabetes, liver disease, renal disease, any other autoimmune or collagen disease. - Lesions showing histological features of dysplasia. - Patients with skin lichen planus lesions.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lycopene Softgel, 10 Mg
Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.
Prednisolone
Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).

Locations

Country Name City State
Egypt Faculty of Dentistry, Alexandria University Alexandria

Sponsors (2)

Lead Sponsor Collaborator
Nourhan M.Aly Alexandria University

Country where clinical trial is conducted

Egypt, 

References & Publications (2)

Gobbo M, Rupel K, Zoi V, Perinetti G, Ottaviani G, Di Lenarda R, Bevilacqua L, Woo SB, Biasotto M. Scoring systems for Oral Lichen Planus used by differently experienced raters. Med Oral Patol Oral Cir Bucal. 2017 Sep 1;22(5):e562-e571. doi: 10.4317/medoral.21833. — View Citation

Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med. 1992 Nov;21(10):456-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Pain assessment was conducted using Visual Analogue Scale (VAS) Patients were instructed to mark a 10 cm line at a point equivalent to their present pain. The score was determined by measuring the distance in mm on the line from the "no pain" anchor to the patient's mark, providing a range of scores from 0-100. A Pain-free experience was scored zero, while the worst pain was scored 100. up to 5 months
Primary Lesion size assessment Assessment of OLP lesions was performed using the Thongprasom et al. scoring index where:
Score 0: No lesion/Normal mucosa.
Score 1: Mild white striae only.
Score 2: White striae with erythematous area <1cm².
Score 3: White striae with erythematous area >1cm².
Score 4: White striae with erosive area <1cm².
Score 5: White striae with erosive area >1cm².
Scores from different oral sites were added to give a final score for every patient from 0-50.
up to 5 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04487938 - Oral Cancer Screening and Education in Hong Kong